Ovid Therapeutics (OVID) Net Income towards Common Stockholders (QoQ) (2016 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Net Income towards Common Stockholders (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.65% |
| Mar 31, 2026 | -275.80% |
| Dec 31, 2025 | 179.48% |
| Sep 30, 2025 | -159.56% |
| Jun 30, 2025 | 54.24% |
| Mar 31, 2025 | -10.61% |
| Dec 31, 2024 | 33.94% |
| Sep 30, 2024 | -264.37% |
| Jun 30, 2024 | 172.87% |
| Mar 31, 2024 | 23.68% |
| Dec 31, 2023 | -36.16% |
| Sep 30, 2023 | 9.31% |
| Jun 30, 2023 | 7.10% |
| Mar 31, 2023 | -16.09% |
| Dec 31, 2022 | 3.87% |
| Sep 30, 2022 | 17.96% |
| Jun 30, 2022 | 9.43% |
| Mar 31, 2022 | 38.05% |
| Dec 31, 2021 | -128.39% |
| Sep 30, 2021 | 27.89% |